FINWIRES · TerminalLIVE
FINWIRES

PYC Therapeutics Advances Optic Atrophy Drug to Multiple-Dose Study After Safety Clearance; Shares Up 7%

By

PYC Therapeutics (ASX:PYC) has been cleared by the safety review committee to advance PYC-001 candidate into a multiple ascending dose study in patients with autosomal dominant optic atrophy (ADOA), following positive four-week safety and tolerability results from the 60 microgram single ascending dose trial, according to a Wednesday filing with the Australian bourse.

The company is currently assessing repeat dosing in ADOA patients to evaluate safety and preliminary efficacy, aiming to establish clinical proof of concept before initiating a global registrational trial to support a new drug application, the filing said.

The results from the ongoing phase one and two multiple ascending dose study will be presented throughout 2026 and 2027, the filing added.

The company's shares rose 7% in recent Wednesday trade.

Related Articles

Asia

Farglory Land Development OKs NT$3.8 Billion Construction Project

Farglory Land Development (TPE:5522) approved a NT$3.8 billion construction contract for a project in Tainan's East District, according to a Monday Taiwan Exchange filing.Shares slid over 1% in Tuesday's late morning trade.The contract involves a joint venture to develop land in the Dongguang Section, with work to be carried out by its unit, Farglory Construction.The project is expected to support future revenue growth upon completion.The company did not disclose a timeline for the project.

TPE:5522
Asia

China Northern Rare Earth Forecasts Up to 118% Rise in Q1 Profit; Shares Fall 4%

China Northern Rare Earth (SHA:600111) expects attributable profit to jump 109% to 118% to between 900 million yuan and 940 million yuan in the first quarter from 430.6 million yuan in the year-ago period, according to a Tuesday filing with the Shanghai bourse.The upbeat forecast is attributable to a price increase in rare earths, as well as cost reduction and risk control, the filing said.Shares fell 4% during the midday break.

SHA:600111
Asia

Sinomach's 2025 Profit Slips 7%, Revenue Jumps 14%; Shares Up 5%

Sinomach Precision Industry's (SHE:002046) net profit attributable to shareholders in 2025 slipped 7% to 260.3 million yuan from 279.8 million yuan a year earlier, according to a Shenzhen bourse filing on Tuesday.Earnings per share fell 8% year on year to 0.49 yuan from 0.53 yuan.Operating revenue jumped 14% to 3.02 billion yuan from 2.66 billion yuan in the previous year.The Chinese industrial equipment manufacturer's shares jumped 5% during the morning trade.

SHE:002046